TRODELVY/SACITUZUMAB GOVITECAN-HZIY 戈沙妥组单抗(trodelvy)

Indications
TRODELVY is used for adult patients with metastatic triple-negative breast cancer (mTNBC) who have previously received at least two therapies.
Dosage and Administration
1. This drug is a prescription drug and is an intravenous infusion; it must be prepared and administered by professional medical staff.
2. This drug is administered once a week on the 1st and 8th days of a 21-day treatment cycle.
3. The first dose of the dose is infused over 3 hours. If the patient can tolerate the first dose well, the subsequent infusion time can be controlled to 1 to 2 hours.
4. Before each dose, medication is required to prevent infusion reactions, such as nausea and vomiting.
5. Patients need to be monitored for adverse reactions during and for at least 30 minutes after each infusion.
6. If the patient has an infusion-related reaction, the medical staff needs to slow down the infusion rate or temporarily stop the infusion; if a life-threatening infusion reaction occurs, the drug may be permanently discontinued for treatment.
7. The duration of treatment is determined by the medical staff.
Storage
Store with original dosage bottle in refrigerator at 2°C to 8°C (36°F to 46°F), keep out of light, do not freeze or shake.

Adverse Reactions
Common adverse reactions include: fatigue; decreased red blood cell count; hair loss; constipation; rash; decreased appetite; stomach area (abdomen) pain, etc.
This drug may cause serious adverse reactions, such as:
1. Neutropenia, symptoms may include: fever, chills, cough, shortness of breath, burning or pain when urinating
2. Severe diarrhea
3. Severe and life-threatening allergic reactions: swelling of the face, lips, tongue or throat; hives; rash or flushing of the skin; difficulty breathing or wheezing; dizziness, feeling weak or fainting; chills or shaking chills; fever, etc.
4. Nausea and vomiting
Other sections of the instructions discuss the above adverse reactions in more detail.